PRospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With ChemoradIotherapy Followed by cONsolidation Therapy With Durvalumab (PRECISION)
Conditions: Oncology; Biomarker; NSCLC, Stage III; Durvalumab; Chemoradiotherapy Intervention: Other: Non-interventional Sponsors: LMU Klinikum; Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany; Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Institute for Medical Information Processing, Biometry and Epi...
Source: ClinicalTrials.gov - August 30, 2021 Category: Research Source Type: clinical trials
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Conditions: Oncology; Biomarker; NSCLC, Stage III; Durvalumab; Chemoradiotherapy Intervention: Other: Non-interventional Sponsors: LMU Klinikum; Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany; Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Institute for Medical Information Processing, Biometry and Epi...
Source: ClinicalTrials.gov - August 30, 2021 Category: Research Source Type: clinical trials
